Journal: Life Metabolism

Article Title: Glucose-6-phosphate dehydrogenase regulates mitophagy by maintaining PINK1 stability

doi: 10.1093/lifemeta/loae040

Figure Lengend Snippet: G6PD is involved in PINK1 stabilization and ubiquitin phosphorylation. (a−f) Detection of p-Ub and PINK1 protein levels by immunoblotting analysis. (a) WT and G6PD KO HeLa 3+ cells were treated with O/A (5 μmol/L and 1 μmol/L, respectively) for the indicated time points and subjected to immunoblotting analysis. (b) G6PD KO HeLa 3+ cells were transfected with WT G6PD for 24 h. Cells were then treated with O/A (5 μmol/L and 1 μmol/L, respectively) for 4 h and subjected to immunoblotting analysis. RE: reconstituted. (c) WT, G6PD KO, and PGLS KO HeLa 3+ cells were treated with O/A (5 μmol/L and 1 μmol/L, respectively) for 4 h. Lysates were subjected to immunoblot analysis. (d) HeLa 3+ cells were pretreated with G6PD inhibitors DHEA (500 μmol/L) or 6-AN (1 mmol/L) for 1 h before O/A (5 μmol/L and 1 μmol/L, respectively) treatment for 2 h. G6PD KO cells were used as a negative control. (e) HeLa 3+ cells were pretreated with BAY (10 μmol/L), PAR (25 μmol/L), or WED (50 μmol/L) for 1 h followed by O/A (5 μmol/L and 1 μmol/L, respectively) treatment for 2 h. G6PD KO cells were used as a negative control. Loading control is shared with . (f) WT and G6PD KO HeLa 3+ cells were pretreated with AG1 (20 μmol/L) for 1 h before O/A (5 μmol/L and 1 μmol/L, respectively) treatment for 4 h. (g) Visualization of mCherry-Parkin translocation by live cell imaging. HeLa 3+ (WT and PINK1 KO) cells were pretreated with AG1 (20 μmol/L) for 1 h before O/A (5 μmol/L and 1 μmol/L, respectively) treatment for 2 h. Images were taken using a Leica fluorescence microscope. Scale bar: 20 μm. (h) Detection of mitochondrial protein levels by immunoblotting. HeLa 3+ (WT and PINK1 KO) cells were pretreated with AG1 (20 μmol/L) for 1 h before O/A (5 μmol/L and 1 μmol/L, respectively) treatment for 4 h. Lysates were subjected to immunoblotting analysis with the indicated antibodies. (i) Mitochondrial protein levels in G6PD-overexpressing cells. G6PD KO and PINK1 KO HeLa 3+ cells were transfected with WT G6PD for 24 h. Cells were treated with O/A (5 μmol/L and 1 μmol/L, respectively) for 4 h before lysis and immunoblotting analysis. (j) Cleaved PINK1 levels observed by immunoblotting analysis. HeLa 3+ (WT and G6PD KO) cells were pretreated with MG132 (10 μmol/L) for 1 h before being treated with O/A (5 μmol/L and 1 μmol/L, respectively) for 4 h. Lysates were immunoblotted with the indicated antibodies.

Article Snippet: AG1 (HY-123962) and Spautin-1 (HY-12990) were purchased from MedChemExpress.

Techniques: Ubiquitin Proteomics, Phospho-proteomics, Western Blot, Transfection, Negative Control, Control, Translocation Assay, Live Cell Imaging, Fluorescence, Microscopy, Lysis

Journal: Human Heredity

Article Title: Reduction of Missed Diagnosis of G6PD Deficiency in Heterozygous Females by G6PD/6PGD Ratio Assay Combined with Amplification Refractory Mutation System PCR

doi: 10.1159/000527806

Figure Lengend Snippet: Results of G6PD/6PGD ratio assay and ARMS/NGS

Article Snippet: The G6PD/6PGD ratio was measured using a commercial G6PD biochemistry reagent kit (fluorescence ratio method) (Guangzhou KOFA Biotechnology Co., Ltd.).

Techniques:

Journal: Human Heredity

Article Title: Reduction of Missed Diagnosis of G6PD Deficiency in Heterozygous Females by G6PD/6PGD Ratio Assay Combined with Amplification Refractory Mutation System PCR

doi: 10.1159/000527806

Figure Lengend Snippet: The number of mutations detected within different G6PD/6PGD ratio intervals

Article Snippet: The G6PD/6PGD ratio was measured using a commercial G6PD biochemistry reagent kit (fluorescence ratio method) (Guangzhou KOFA Biotechnology Co., Ltd.).

Techniques:

Journal: PLOS Neglected Tropical Diseases

Article Title: Clinical performance validation of the STANDARD G6PD test: A multi-country pooled analysis

doi: 10.1371/journal.pntd.0011652

Figure Lengend Snippet: Summary of demographics.

Article Snippet: In practice, the implementation of such tests has been challenging as described in a recent publication from the College of American Pathologists as well as meta-analysis spectrophotometry-based quantification of G6PD activity [ , ].

Techniques:

Journal: PLOS Neglected Tropical Diseases

Article Title: Clinical performance validation of the STANDARD G6PD test: A multi-country pooled analysis

doi: 10.1371/journal.pntd.0011652

Figure Lengend Snippet: Adjusted G6PD normal male median (AMM) and analytical population male medians on the reference assay at the Porto Velho, Brazil, and Kolkata, India, sites, by P . vivax malaria status.

Article Snippet: In practice, the implementation of such tests has been challenging as described in a recent publication from the College of American Pathologists as well as meta-analysis spectrophotometry-based quantification of G6PD activity [ , ].

Techniques:

Journal: PLOS Neglected Tropical Diseases

Article Title: Clinical performance validation of the STANDARD G6PD test: A multi-country pooled analysis

doi: 10.1371/journal.pntd.0011652

Figure Lengend Snippet: Summary diagnostic performance of the STANDARD G6PD Test for identifying G6PD deficient males and females and females with intermediate G6PD activity, by specimen type, in all study participants and in P . vivax cases only.

Article Snippet: In practice, the implementation of such tests has been challenging as described in a recent publication from the College of American Pathologists as well as meta-analysis spectrophotometry-based quantification of G6PD activity [ , ].

Techniques: Diagnostic Assay, Activity Assay, Infection

Journal: PLOS Neglected Tropical Diseases

Article Title: Clinical performance validation of the STANDARD G6PD test: A multi-country pooled analysis

doi: 10.1371/journal.pntd.0011652

Figure Lengend Snippet: G6PD status classification measured by the STANDARD G6PD Test is shown on the X-axis, for capillary (grey) and venous (black) specimens, respectively. Results are plotted by the reference G6PD percent activity (Y-axis). Shaded areas correspond to true G6PD normal (green), intermediate (yellow), and deficient (red) status classifications on the reference assay.

Article Snippet: In practice, the implementation of such tests has been challenging as described in a recent publication from the College of American Pathologists as well as meta-analysis spectrophotometry-based quantification of G6PD activity [ , ].

Techniques: Activity Assay

Journal: PLOS Neglected Tropical Diseases

Article Title: Clinical performance validation of the STANDARD G6PD test: A multi-country pooled analysis

doi: 10.1371/journal.pntd.0011652

Figure Lengend Snippet: 2 x 2 and 3 x 3 tables for males and female G6PD classifications respectively by the reference assay (columns) and by the STANDARD G6PD test (rows). 30% and 70% normal G6PD activity thresholds were used to classify G6PD deficient and intermediate status, respectively, with the reference spectrophotometric assay. Manufacturer thresholds on the STANDARD G6PD test were used to classify G6PD deficient and intermediate status.

Article Snippet: In practice, the implementation of such tests has been challenging as described in a recent publication from the College of American Pathologists as well as meta-analysis spectrophotometry-based quantification of G6PD activity [ , ].

Techniques: Activity Assay, Spectrophotometric Assay, G6PD Assay

Journal: PLOS Neglected Tropical Diseases

Article Title: Clinical performance validation of the STANDARD G6PD test: A multi-country pooled analysis

doi: 10.1371/journal.pntd.0011652

Figure Lengend Snippet: Performance indicators applying the 6.0 U/g Hb threshold on the STANDARD G6PD Test for deficient and intermediate females with G6PD activity levels between 0% and 40%, 50%, 60%, 65%, and 70% for capillary specimens.

Article Snippet: In practice, the implementation of such tests has been challenging as described in a recent publication from the College of American Pathologists as well as meta-analysis spectrophotometry-based quantification of G6PD activity [ , ].

Techniques: Activity Assay

Journal: PLOS Neglected Tropical Diseases

Article Title: Clinical performance validation of the STANDARD G6PD test: A multi-country pooled analysis

doi: 10.1371/journal.pntd.0011652

Figure Lengend Snippet: Panels A and B represent eligibility and outcomes for daily primaquine regimen. Panels C and D represent eligibility and outcomes for tafenoquine and daily primaquine, with those who are considered ineligible for tafenoquine then considered for primaquine eligibility. Abbreviations: G6PD, glucose-6-phosphate-dehydrogenase; PQ, Primaquine; Hb, Hemoglobin; TQ, Tafenoquine. * No other treatment eligibility criteria (e.g., age, anemia status, pregnancy status) were considered as part of the calculation.

Article Snippet: In practice, the implementation of such tests has been challenging as described in a recent publication from the College of American Pathologists as well as meta-analysis spectrophotometry-based quantification of G6PD activity [ , ].

Techniques: